All In Biotech

Drug Trial Radar · NCT07023432

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Nov 17, 2025

Primary completion

Apr 14, 2028

Study completion Apr 14, 2030

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To learn if belzutifan can help to control the disease in patients with metastatic RCC who are considered candidates for active surveillance and have not undergone previous systemic treatment. The safety of belzutifan in this patient population will also be studied.

Conditions

  • Active Surveillance
  • Clear Cell Renal Cell Carcinoma

Interventions

  • BelzutifanDrug

    Given by PO

  • Active SurveillanceOther

    Given by Observation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse events (AEs)Time frame: Through study completion; an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.